Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

Biological Psychiatry

Volumn 49, Issue 3, 2001, Pages 279-288

  Maelicke, Alfred ^a   Samochocki, Marek ^a   Jostock, Ruth ^a   Fehrenbacher, Andreas ^a   Ludwig, Jürgen ^a   Albuquerque, Edson X ^a   Zerlin, Marion ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

4 2 nAChR; 7 5HT 3 chimeric nAChR; Allosterically potentiating ligand; Cholinesterase inhibitor; Codeine; Donepezil; Galantamine; Metrifonate; Nicotinic acetylcholine receptor; Physostigmine; Rivastigmine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; ESTERASE; GALANTAMINE; NICOTINIC RECEPTOR; TACRINE;

ALLOSTERISM; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; NERVE CELL; PALLIATIVE THERAPY; PATCH CLAMP; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; TREATMENT OUTCOME;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ALZHEIMER DISEASE; ANIMALS; CELL LINE; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS; MICE; NEURONS; NOOTROPIC AGENTS; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC;

EID: 0035251675     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01109-4     Document Type: Review

References (75)

1. Properties of neuronal nicotinic acetylcholine receptors, pharmacological characterization and modulation of synaptic function
2. Neuronal nicotinic receptors and synaptic transmission in the mammalian central nervous system
3. α7 nicotinic acetylcholine receptor and modulation of gabaergic synaptic transmission in the hippocampus
4. Choline is a selective agonist of a7 nicotinic acetylcholine receptors
5. Nicotinic receptor activation in human cerebral cortical interneurons: A mechanism for inhibition and disinhibition of neuronal networks
6. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices
7. The cholinergic hypothesis of geriatric memory dysfunction
8. Pharmacology of nicotine: Addiction and therapeutics
9. Nicotinic receptor: An allosteric protein specialized for intercellular communication
10. Allosteric modulation of neuronal nicotinic acetylcholine receptors
11. α-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability
12. Cigarette smoking and major depression
13. Cholinergic underactivity in human memory disorders
14. The hypothesis of an ambient level of acetylcholine in the central nervous system
15. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: An open study
16. Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specifities
17. The cholinergic hypothesis of Alzheimer's disease: A review of progress
18. Linkage of neurophysiological deficit in schizophrenia to a chromosome 15 locus
19. Acetylcholinesterase-induced β-amyloid aggregation and neurotoxicity
20. NBD-5-acetylcholine: Fluorescent analog of acetylcholine and agonist at the neuromuscular junction
21. A reexamination of curare action at the motor endplate
22. Acute stress facilitates long-lasting changes in cholinergic gene expression
23. Stimulation of α4β2 nicotinic receptors inhibits β-amyloid toxicity
24. Ivermectin: A positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor
25. Regulation of βAPP processing with cholinesterase inhibitors in neuronal cell lines
26. Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease
27. Nicotinic acetylcholine receptors in health and disease
28. Biochemical aspects of cholinergic excitation
29. New approach to drug therapy in Alzheimer's disease
30. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
31. Neuronal nicotinic acetylcholine receptors in non-neuronal cells, expression and renaturation of ligand binding domain and modulatory control by allosterically acting ligands
32. Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system
33. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors
34. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment
35. α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease
36. Kinetic properties and regulation of GABA receptor channels
37. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior
38. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics
39. Intravenous nicotine in Alzheimer's disease: A pilot study
40. Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system
41. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains: In vivo assessment using positron emission tomography
42. The role of nicotinic receptors in the pathophysiology of Alzheimer's disease
43. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
44. 3H) acetylcholine binding sites in the frontal cortex of Alzheimer brains
45. Chronic nicotine treatment upregulates α3 AChRs and α7 AChRs expressed by the human neuroblastoma cell line SH-SY5Y
46. Physostigmine and galantamine: Probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells
47. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons
48. Increased nicotinic receptors in brains from smokers: Membrane binding and autoradiography studies
49. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology
50. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease
51. Presynaptic muscarinic receptors in the central nervous system
52. Enhancement of glycine release from human brain cortex synaptosomes by acetylcholine acting at M4 muscarinic receptors
53. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease
54. Ligand binding and activation of rat nicotinic α4β2 receptors stably expressed in HEK293 cells
55. Galantamine is an allosterically potentiating ligand of the human α4β2 nAChR
56. Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine
57. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands
58. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor a-polypeptide
59. Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer's disease
60. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex
61. Transdermal nicotine in Tourette's syndrome
62. Multifaced role of acetylcholinesterase in Alzheimer's disease
63. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha4 subunit is associated with autosomal dominant noctural frontal lobe epilepsy
64. Stable expression in HEK-293 cells of the rat α3/β4 subtype of nicotinic acetylcholine receptor
65. Physostigmine, galantamine and codeine act as non-competitive nicotinic agonists on clonal rat pheochromocytoma cells
66. Tacrine interacts with an allosteric activator site on α4/β2 nAChRs in M10 cells
67. A 24-week randomized trial of controlled-release phsyostigmine in patients with Alzheimer's disease
68. β-Amyloid(1-42) binds to α7 nicotinic acetylcholine receptor with high affinity
69. Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains
70. Basal forebrain neurons in the dementia of Parkinson disease
71. Nicotinic acetylcholine binding sites in Alzheimer's disease
72. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory and safety
73. Nicotine: Not just for cigarettes anymore
74. Physostigmine potentiates α4β4 nAChR by a competitive mechanism
75. Potentiation and inhibition of neuronal nicotinic receptors by atropine: Competitive and noncompetitive effects